Diplomat Caesarea: When the New Logistics Center Starts Creating Value Instead of Just Consuming Capital

The main article already framed Diplomat through the broader capital question. This follow-up isolates only Caesarea: when the new logistics center can start creating value, and how CDSL turns it from a large logistics project into an execution and capital-allocation issue with timelines, rent, FX and an expensive bridge period.

The easy mistake is to read Caesarea as a ribbon-cutting story. The filing says something else. Value does not start when the building stands. It starts only when the site runs at enough throughput, migrates CDSL without hurting service levels, and can absorb both the rent layer and the automation layer without a long overlap period and without further overruns.

Four points frame the picture already now:

• Caesarea is already inside the 2025 numbers. PP&E rose mainly because of roughly NIS 64 million of project investment, and another NIS 40 million was paid as lease advances instead of future lease payments.
• The economics start with rent, not only with capex. The lease term is 24 years and 11 months, and annual rent is based on land value plus actual construction cost at about 7.35%, CPI linked.
• CDSL is not optional upside. It is the utilization anchor of the new site, with a contract through 2041 with Super-Pharm, but it is also the channel through which milestone and penalty risk runs.
• The disclosure still does not reconcile into one clean project map. The operating chapter refers to roughly EUR 60 million of steel investment, while note 10(c) describes a steel contract of EUR 19.1 million.

Caesarea is already on the balance sheet, before it creates a single shekel of value

What matters about Caesarea is that the project has long since moved from story to absorption. At the end of 2025 group PP&E rose to NIS 213.5 million from NIS 143.4 million, and the directors' report ties most of the increase to roughly NIS 64 million of investment in the project. At the same time, other long-term assets jumped to NIS 44.7 million from NIS 0.8 million, mainly because NIS 40 million was paid to the Caesarea landlord in lieu of future lease payments. Assets under construction also reached NIS 138.4 million. So even before discussing efficiency gains or a shorter distribution route, there is already both capex and prepaid rent sitting in the numbers.

The filing adds two more layers that are easy to miss if one reads only the headlines. The first is financing. The Caesarea loan taken in December 2021 stood at NIS 100.5 million at the end of 2025, at an annual rate of 2.6%, after being taken originally at NIS 103 million. The second is FX. The company designated foreign-currency forward contracts as hedging instruments for fixed-asset purchases, and by the end of 2025 their fair value was already a NIS 11.7 million liability. In 2025 the company also recorded net cash payments of NIS 1.8 million from derivative settlements.

The implication is straightforward: Caesarea is no longer a future option on efficiency. It is already hitting the balance sheet, the cash-flow statement and the FX line in 2025. That is the core distinction between a project whose economics can be postponed until launch and a project that already has to be measured in capital, cash and execution terms.

The real economic test starts with rent, not with the opening day

This is where it is easy to misread the project. A reader who sees an estimated construction cost of roughly NIS 650 million may think the question is simply how much capex is still left. But the economics of Caesarea are more complex. The Caesarea landlord bears construction, planning and financing costs up to about NIS 500 million, excluding the land component, while Diplomat leases the site for 24 years and 11 months at annual rent of about 7.35% on full land value plus actual construction cost, CPI linked. Beyond that cap, design changes requested by Diplomat can either be prepaid or added to the cost base.

That means Caesarea cannot be assessed only through the investment line. It has to be assessed through the rent layer that comes with commissioning. In a simple arithmetic exercise, NIS 500 million of construction cost alone implies annual rent of about NIS 36.8 million, before land value and before CPI linkage. This is not management guidance. It is just the direct output of the disclosed rent formula. That is precisely why it matters: it shows how much utilization Caesarea needs before it creates value rather than just opening a new building.

And that still excludes the equipment layer that Diplomat is building on its own account. Note 10(c) explicitly says the company itself will build the full automated shelving and robotics stack, estimated at about EUR 81 million as of the report date. So the economic model of the new site stands on two separate legs: a long-term rent obligation to the landlord, and a capital layer that remains on Diplomat's own balance sheet.

That chart sharpens another point. Even at the euro level, this is not one project with one clean number. There is an EUR 81 million estimate for the automation and robotics layer, an automation agreement of roughly EUR 39 million, an additional automation layer of EUR 17.9 million, and a steel agreement of EUR 19.1 million under note 10(c). In other words, anyone trying to understand when Caesarea starts working for shareholders cannot stop at the headline of a new logistics center. They have to ask how much of the envelope is already contracted, how much is still ahead of payment, and how all of that sits against a long-dated annual rent burden.

CDSL is the bridge between a real-estate project and a real economic story

This is where CDSL comes in, and without it Caesarea is hard to read correctly. Diplomat Israel holds 50% of the company, and the other 50% is held by the other shareholder. Under the October 2020 agreement, CDSL provides logistics and warehouse-management services to Super-Pharm for the general-merchandise department through 2041. Compensation is based on the number of operations CDSL performs, such as pallet receiving, unloading, storage and value-added work. At the same time Diplomat committed to build a mostly automated logistics center and lease part of it to CDSL.

That is the heart of the story. CDSL is not just a future subtenant. It is the utilization anchor of Caesarea. Without it, the new site is first and foremost a large rent obligation plus a heavy automation investment. With it, there is at least a clearer path to turning scale, automation and service into something that can earn back the capital.

But the same channel that brings volume also brings execution risk. The Super-Pharm agreement states that if Diplomat does not meet the logistics-center milestones, or if CDSL does not provide services as required, Super-Pharm can impose delay penalties and in certain cases cancel the agreement. The filing adds one critical detail: close to the report date the company and CDSL were already working to extend those milestone dates and amend additional terms in the agreement. So timeline risk is no longer a tail scenario. It has already reached the stage of reopening the contract.

The current CDSL layer is also already visible in the numbers, before Caesarea. Diplomat has leased the Ayal logistics center since December 2020 and subleases it in full to CDSL. All three extension options were exercised, and in the first quarter of 2025 the company entered another option period and recognized an increase of roughly NIS 32 million in net lease investment and lease liability. By the end of 2025 finance-lease receivables stood at NIS 47.2 million.

The point of that chart is not that Ayal is the major value engine. Quite the opposite. It shows that CDSL economics already exist today in an interim structure, with undiscounted lease collections of NIS 19.4 million, NIS 18.3 million and NIS 12.5 million over the next three years. So the move to Caesarea is not the creation of a business layer from zero. It is the migration of an existing layer into a much heavier capital base. If that migration works, Caesarea can become a more efficient platform. If it slips, the company can end up carrying an interim economic structure in the old site and a capital-heavy structure in the new site at the same time.

The bottleneck is the bridge years, not opening day

The filing lays out a timeline that has to be read slowly. Construction started in August 2024. Steel works, under note 10(c), are planned to finish in July 2026. The automation system is planned to be installed and operational by the end of October 2027. The operating chapter adds that the logistics center itself is expected to be completed in December 2027, with operations after system runs expected during the second quarter of 2028.

In other words, even without another slippage, there are still roughly two and a half years between capital already burned and value still not proven. And here one easy-to-miss detail becomes important: the existing Airport City logistics center was already extended in August 2024 through August 31, 2028, at NIS 65 per square meter on roughly 30,383 square meters. That is a simple arithmetic exercise that points to an annual rent run rate of about NIS 23.7 million before ancillary costs. So even in the base case where Caesarea starts operating in the second quarter of 2028, the timeline already contains overlap with the existing site. The double-rent risk does not appear only if something goes wrong. It is already built into the structure of the project, and every delay just makes it larger.

The company itself does not hide the risk. The risk section explicitly says that the complexity of the project, the dependence on the main contractor, the automation contractor and the racking contractor, and the complexity of running the systems could delay full operations in Caesarea for both Diplomat and CDSL, increase actual costs and create double-rent payments. It also says delays could lead to disagreements with the Caesarea landlord over the actual handover date. This is no outside bear thesis. It is the risk language the company chose to write.

What the filing still does not close out

Precisely because Caesarea is already large enough to analyze on its own, what the filing still does not reconcile becomes more visible. The clearest example is the steel layer. The operating chapter says the steel investment is expected to total roughly EUR 60 million. Note 10(c), describing the same May 2, 2024 agreement, refers to consideration of EUR 19.1 million, of which EUR 11 million had already been paid by the end of 2025. It is hard to build a clean capex map when the same filing speaks in two different numbers about the same layer.

Automation also remains partly open. On one hand there is the EUR 81 million estimate for the full automated shelving and robotics layer. On the other, the disclosed automation agreements total EUR 39 million plus EUR 17.9 million. The gap may reflect additional components, adjustments or other system layers. But the filing does not give the reader a full bridge between the overall estimate and the contracts already signed.

The same is true for hedging. What the filing does provide is that the company hedges fixed-asset purchases in foreign currency through forward contracts designated as cash-flow hedges, and that the related liability stood at NIS 11.7 million at the end of 2025. What it does not provide is a full reconciliation between the euro commitment envelope and the hedge envelope. So it is still hard to answer with full confidence how much exposure is already locked and how much can still move as the project progresses.

Those gaps do not cancel the strategic logic of Caesarea. They simply mean that in 2025 the project is still hard to read as one closed economic unit. And when a project is already consuming capital, that is a material point rather than a footnote.

Conclusion

The continuation thesis here is simple: Caesarea starts creating value only when it moves from a shell of capital, rent and milestones into a platform that actually carries volume, service and utilization. As of the end of 2025 it is not there yet. The money has already gone out, the rent formula is already disclosed, CDSL already ties the project to a long-term Super-Pharm contract, but the bridge years are still ahead.

The strongest counter-thesis is that this is exactly the infrastructure investment the group should be making: a site designed for 20 years of natural growth, new categories, frozen and chilled products, CDSL and e-commerce, with long-dated demand support through Super-Pharm. That is a serious argument. The problem is that 2025 still gives the reader the initial bill, not the proof.

So the four real checkpoints for the next 2 to 4 quarters are not construction headlines. They are the harder questions: whether the milestone extension with Super-Pharm is closed without material damage to CDSL economics, whether the euro commitment map becomes clearer, whether the move to Caesarea shortens rather than extends the double-rent period, and whether the company can keep the project inside a digestible capital envelope before go-live. Until those answers arrive, Caesarea is first a project asking investors for capital patience, and only after that a value-creation story.